T1	Participants 140 229	patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial
T2	Participants 495 511	myeloma patients
T3	Participants 628 784	CD19+ B cells by flow cytometry in previously untreated newly diagnosed myeloma patients in Eastern Cooperative Oncology Group (ECOG) phase III trial E9486.
T4	Participants 796 954	628 patients who were eligible for the clinical protocol E9486, but of these 521 were also entered on the companion laboratory study (E9487) and had CD19 data
